AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32278771
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal 0.5 mg ranibizumab
Trial: 32278771
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal 0.5 mg ranibizumab plus TRP
Trial: 32278771
Drug: 3 monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP
Trial: 32769639
Drug: Interpersonal therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal therapy-based intervention (n=129)
Trial: 37866373
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for 7 days
Trial: 32122863
Drug: Staging acupuncture
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staging acupuncture treatment after stroke
Trial: 32596297
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy (AIT) for 3 years
Trial: 32245197
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (0.33 g·kg−1·d−1 protein)
Trial: 32245197
Drug: Control (isonitrogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isonitrogenous control, 0.33 g·kg−1·d−1 protein)
Trial: 33285602
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (1.4 mg elemental Zn/kg/d orally for 10 days)
Trial: 32089329
Drug: Triple fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple fixed combination (TFC) of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution
Trial: 32089329
Drug: Dual fixed
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual fixed combination (DFC) of brimonidine 0.2%/timolol 0.5%
Trial: 34512959
Drug: Niclosamide (NCS)
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide (NCS) as add-on therapy to standard of care
Trial: 34512959
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy only (Control)
Trial: 33421836
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide gas (N2O) administration during childbirth
Trial: 33421836
Drug: Morphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administration during childbirth
Trial: 33421836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both drugs with severe pain during labor
Trial: 33010242
Drug: Tetravalent vaccine
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent vaccine (Ad26.Mos4.HIV)
Trial: 35665918
Drug: NRTIs included
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NRTIs included in the treatment regimen
Trial: 35665918
Drug: NRTIs omitted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs omitted from the treatment regimen
Trial: 33931178
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with a central action mechanism
Trial: 33931178
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with a peripheral action mechanism
Trial: 33931178
Drug: Dopamine antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine antagonists (specific drug type not mentioned)
Trial: 35854251
Drug: Simultaneous PTSD
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous PTSD treatment
Trial: 35854251
Drug: Sequential PTSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential PTSD treatment
Trial: 33609066
Drug: Hypokalaemia (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypokalaemia (serum potassium <4 mmol/L)
Trial: 33609066
Drug: Hyperkalaemia (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperkalaemia (serum potassium >5 mmol/L)
Trial: 33609066
Drug: Normokalaemia (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normokalaemia (serum potassium 4–5 mmol/L)
Trial: 34726661
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (ET) for 12 weeks
Trial: 32450367
Drug: Intensive Behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Behavioral Therapy (IBT) alone
Trial: 32450367
Drug: Intensive Behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Behavioral Therapy (IBT) with liraglutide 3.0 mg/d
Trial: 32450367
Drug: Intensive Behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Behavioral Therapy (IBT) with liraglutide and a 12-week meal replacement diet (Multi-component)
Trial: 32450367
Drug: Self-monitoring and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring and medication adherence
Trial: 35947347
Drug: Triptorelin pamoate
RxNorm normalized name: Triptorelin Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks)
Trial: 35947347
Drug: Triptorelin acetate
RxNorm normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks)
Trial: 33298201
Drug: Lutein 20
RxNorm normalized name: lutein 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein 20 mg/d along with a low-calorie diet (LCD) for 10 weeks
Trial: 33785016
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg/day for one week before surgery and 60 mg/day for six weeks after surgery)
Trial: 32693847
Drug: Enzymes (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzymes (300 mg/kg)
Trial: 32693847
Drug: Bacillus subtilis
RxNorm normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus subtilis DSM 29784 and Enzymes (1×10^9 cfu/kg and 300 mg/kg)
Trial: 32693847
Drug: Enramycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enramycin (250 mg/kg)
Trial: 38153624
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Trial: 36646196
Drug: Rivaroxaban 5
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg twice daily alone
Trial: 630982953
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg alone
Trial: 32649352
Drug: Rivaroxaban and
RxNorm normalized name: rivaroxaban and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban and aspirin
Trial: 35284698
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine plus ibuprofen (5 mg morphine with 800 mg ibuprofen)
Trial: 35284698
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine plus ketorolac (5 mg morphine with 30 mg ketorolac)
Trial: 35284698
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine alone (5 mg morphine)
Trial: 32611242
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester-enriched spread (3.0 g plant stanols/d)
Trial: 33128847
Drug: Generic pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic pantoprazole sodium enteric-coated tablets
Trial: 33128847
Drug: Branded pantoprazole
RxNorm normalized name: Protium brand of pantoprazole sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded pantoprazole sodium enteric-coated tablets
Trial: 33128847
Drug: Generic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic and branded pantoprazole sodium enteric-coated tablets
Trial: 32370731
Drug: Oral 600mg
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 600mg ALA twice daily for 6 months
Trial: 36890541
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) administration (1000 mg before skin incision and 6 hours after)
Trial: 36890541
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without TXA administration)
Trial: 36890541
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) administration
Trial: 34936382
Drug: All subjects
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects receiving antibiotics
Trial: 32217888
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (electro or sham)
Trial: 32217888
Drug: Pharmacological hot
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological hot flash treatment (gabapentin or placebo)
Trial: 34432899
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (2.2 mg on days 1 and 2; 13.2 mg on days 3 and 4)
Trial: 34432899
Drug: Voriconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (400 mg twice on day 1, then 3 doses of 200 mg every 12 hours)
Trial: 33181558
Drug: Closed-loop BIS-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop BIS-guided propofol and remifentanil titration
Trial: 33181558
Drug: Manual BIS-guided
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual BIS-guided propofol and remifentanil titration
Trial: 34953469
Drug: RA1 mouth
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA1 mouth rinse solution (0.8% proanthocyanidin-enriched extract from Rumex acetosa)
Trial: 32446304
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride gargle (15 mL of 0.15% solution)
Trial: 32053298
Drug: Reduced-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose regimen of oral glucocorticoids
Trial: 32053298
Drug: Standard-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose regimen of oral glucocorticoids
Trial: 32741789
Drug: Mismatch (Mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mismatch (Mg) group using the Te.M.P.O. application
Trial: 34038198
Drug: 0.75% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% isobaric ropivacaine plus 5 µg sufentanil intrathecally (Group RS)
Trial: 32062566
Drug: Real treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real treatment (rTMS)
Trial: 35652434
Drug: Two daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily applications of 1 h each
Trial: 32980290
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid (180 mg once daily for 12 to 52 weeks)
Trial: 32980290
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 12 to 52 weeks)
Trial: 33155505
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet rich fibrin mixed with antibiotics (Colistin, Ciprofloxacin‐Colistin combination, Tobramycin)
Trial: 33155505
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet rich fibrin mixed with antibiotics
Trial: 32675314
Drug: Nasal Continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Continuous Positive Airway Pressure (nCPAP) administered in tertiary centers for term babies for <24 hours
Trial: 34139357
Drug: Perianal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perianal injection with bulking agents (INJ)
Trial: 35683992
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day RMD
Trial: 35683992
Drug: 25 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/day RMD
Trial: 34750035
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus Ipilimumab (NIVO+IPI) every 3 weeks for four doses followed by Nivolumab monotherapy
Trial: 35500098
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin (high-dose group)
Trial: 35500098
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg atorvastatin (low-dose group)
Trial: 35635580
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (endocrine therapy + chemotherapy)
Trial: 33831632
Drug: Incentives for
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Incentives for medication adherence
Trial: 34143714
Drug: Experiential/traditional music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential/traditional music therapy (MG group)
Trial: 34143714
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with experiential/traditional music and acupuncture (AP/MG group)
Trial: 33467421
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) - 30 inspiratory efforts twice daily, 5 days a week, at 50%, 60%, 70%, and 80% of maximum inspiratory pressure (MIP) for 4 weeks
Trial: 33545749
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous infusion (control)
Trial: 32665179
Drug: Preoperative ultrasound-guided
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative ultrasound-guided TTMPB with 20 mL of 0.25% bupivacaine
Trial: 34255199
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + sterile saline solution (SSL)
Trial: 34255199
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + 2% chlorhexidine gel (CHX gel)
Trial: 36669426
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant radiation therapy (RT) 60Gy/30 fractions over 6 weeks
Trial: 36669426
Drug: Accelerated radiation
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiation therapy (6 d a week)
Trial: 36669426
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-risk features (T3-T4 primary tumours with N2-N3 nodes along with ECE)
Trial: 34190016
Drug: Bedtime hypertension
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime hypertension chronotherapy (ingestion of BP-lowering medications at bedtime)
Trial: 34190016
Drug: Upon-waking/morning hypertension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon-waking/morning hypertension treatment-time scheme
Trial: 34039478
Drug: Aminoglycosides (amikacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides (amikacin and gentamicin) administered during CRRT.
Trial: 34039478
Drug: Inappropriate reinjection
RxNorm normalized name: vaccinia virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate reinjection threshold for gentamicin (>2 mg/L) and amikacin (>5 mg/L).
Trial: 32196898
Drug: Outpatient oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient oral treatment (cefixime)
Trial: 32196898
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (cefepime)
Trial: 32803560
Drug: Medication dispensing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication dispensing errors
Trial: 32803560
Drug: Prescription related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription related errors
Trial: 32803560
Drug: Wrong drug
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrong drug errors
Trial: 33173165
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to standard adjuvant chemotherapy (FOFOX or XELOX)
Trial: 33173165
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy (FOFOX or XELOX) without bevacizumab
Trial: 32958269
Drug: Water-only fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-only fasting for 24 hours before and 24 hours after each chemotherapy cycle
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB)
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB) after enrolment
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB) in TNBC
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB) in RAM arm
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB) after enrolment in RAM arm
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB) and treatment-emergent hypertension
Trial: 616063474
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (BB) and treatment arm interaction
Trial: 34226218
Drug: Microablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microablative fractional radiofrequency (MAFRF) treatment
Trial: 33955835
Drug: VR cognitive
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR cognitive training (multidomain and neuropsychologist-assisted) in a fully immersive VR environment, twice a week for 1 month
Trial: 33955835
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual therapy such as pharmacotherapy)
Trial: 32602000
Drug: Combination method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination method using CEUS and blue dye (BD)
Trial: 34159732
Drug: Rectus sheath
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectus sheath block (RSB) with 10 mL of 0.375% ropivacaine
Trial: 34159732
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (LA) with subcutaneous and fascial injection of 10 mL of 0.75% ropivacaine
Trial: 32731841
Drug: Colon capsule
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon capsule endoscopy (CCE)